Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects
Impaired premorbid functioning prior to the onset of acute psychosis has frequently been noted in schizophrenia. This study examined retrospectively the premorbid status of patients in their first episode of psychosis in order to determine relationships with baseline symptoms, treatment response, an...
Gespeichert in:
Veröffentlicht in: | Schizophrenia bulletin 2004-01, Vol.30 (2), p.265-278 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 278 |
---|---|
container_issue | 2 |
container_start_page | 265 |
container_title | Schizophrenia bulletin |
container_volume | 30 |
creator | Strous, Rael D. Alvir, Jose Ma. J. Robinson, Delbert Gal, Gilad Sheitman, Brian Chakos, Miranda Lieberman, Jeffrey A. |
description | Impaired premorbid functioning prior to the onset of acute psychosis has frequently been noted in schizophrenia. This study examined retrospectively the premorbid status of patients in their first episode of psychosis in order to determine relationships with baseline symptoms, treatment response, and medication side effects. One hundred eleven schizophrenic and schizoaffective patients participating in a large prospective study of first episode schizophrenia were evaluated with the Premorbid Adjustment Scale (PAS). Premorbid functioning in males became progressively worse over time. Deficit state patients exhibited worse premorbid functioning. A third of patients exhibited sustained poor premorbid functioning. At various developmental stages, lower "sociability and withdrawal" scores correlated with increased time to treatment response, more severe negative symptoms, increased drug-induced parkinsonism, and deterioration of premorbid functioning. Various mean PAS scores predicted susceptibility to tardive dyskinesia. Our findings suggest that prior to acute psychosis onset there are certain behavioral precursors reflected in premorbid functioning that may predict subsequent illness manifestations. Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms. |
doi_str_mv | 10.1093/oxfordjournals.schbul.a007077 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20247188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>614391453</sourcerecordid><originalsourceid>FETCH-LOGICAL-a527t-88711f27fc8462e428d1bbe95383eecd4806531e73307e573b9a4fee9604a9403</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEokPhFZCFVDY0g_8Sx5VY0KoFpCIQU9aW49wwrhI72E7F9OnxKIP4WbDywt-x7z1fUZwQvCZYstf-R-9Dd-vn4PQQ19Fs23lYa4wFFuJBsSKCVyURmDwsVrhq6lLUhB8VT2K8xZhwWdPHxRGpqJCYV6vi7nOA0YfWduhqdiZZ76z7hqxDG7O1937aBnBWn6EvMOj9LUoenesIg3WANrtxSn6Mp-gmgE4juJTBOHkX4RRp16GP0FmzBDe2A3TZ92BSfFo86vP48OxwHhdfry5vLt6X15_efbh4e13qPGEqm0YQ0lPRm4bXFDhtOtK2ICvWMADT8QbXFSMgGMMCKsFaqXkPIGvMteSYHRcvl3en4L_PEJMabTQwDNqBn6OimHJBmiaDL_4Bf1Wscn9MEl6x_0GUsopXnNMMvVkgE3yMAXo1BTvqsFMEq71C9bdCtShUB4U5__zwydyO0P1OH5xl4OQA6Gj00AftjI1_cJJKUu93f7VwetJqijujQ7JmgGjmkKUmFe9bxbCiiuYSfwIRxbvv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>614391453</pqid></control><display><type>article</type><title>Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>APA PsycARTICLES</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Strous, Rael D. ; Alvir, Jose Ma. J. ; Robinson, Delbert ; Gal, Gilad ; Sheitman, Brian ; Chakos, Miranda ; Lieberman, Jeffrey A.</creator><creatorcontrib>Strous, Rael D. ; Alvir, Jose Ma. J. ; Robinson, Delbert ; Gal, Gilad ; Sheitman, Brian ; Chakos, Miranda ; Lieberman, Jeffrey A.</creatorcontrib><description>Impaired premorbid functioning prior to the onset of acute psychosis has frequently been noted in schizophrenia. This study examined retrospectively the premorbid status of patients in their first episode of psychosis in order to determine relationships with baseline symptoms, treatment response, and medication side effects. One hundred eleven schizophrenic and schizoaffective patients participating in a large prospective study of first episode schizophrenia were evaluated with the Premorbid Adjustment Scale (PAS). Premorbid functioning in males became progressively worse over time. Deficit state patients exhibited worse premorbid functioning. A third of patients exhibited sustained poor premorbid functioning. At various developmental stages, lower "sociability and withdrawal" scores correlated with increased time to treatment response, more severe negative symptoms, increased drug-induced parkinsonism, and deterioration of premorbid functioning. Various mean PAS scores predicted susceptibility to tardive dyskinesia. Our findings suggest that prior to acute psychosis onset there are certain behavioral precursors reflected in premorbid functioning that may predict subsequent illness manifestations. Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms.</description><identifier>ISSN: 0586-7614</identifier><identifier>EISSN: 1745-1701</identifier><identifier>DOI: 10.1093/oxfordjournals.schbul.a007077</identifier><identifier>PMID: 15279045</identifier><identifier>CODEN: SCZBB3</identifier><language>eng</language><publisher>Oxford: National Institute of Mental Health</publisher><subject>Adjustment Disorders - epidemiology ; Adjustment Disorders - etiology ; Adolescent ; Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Basal Ganglia Diseases - chemically induced ; Basal Ganglia Diseases - epidemiology ; Biological and medical sciences ; Brief Psychotic Disorder ; Cognition Disorders - diagnosis ; Cognition Disorders - etiology ; Drug Therapy ; Female ; Human ; Humans ; Inpatient ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Premorbidity ; Psychiatric Symptoms ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychotic Disorders - complications ; Psychotic Disorders - drug therapy ; Retrospective Studies ; Schizoaffective Disorder ; Schizophrenia ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Schizophrenia - epidemiology ; Sex Factors ; Side Effects (Drug) ; Social Alienation</subject><ispartof>Schizophrenia bulletin, 2004-01, Vol.30 (2), p.265-278</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Superintendent of Documents 2004</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a527t-88711f27fc8462e428d1bbe95383eecd4806531e73307e573b9a4fee9604a9403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15929160$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15279045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Strous, Rael D.</creatorcontrib><creatorcontrib>Alvir, Jose Ma. J.</creatorcontrib><creatorcontrib>Robinson, Delbert</creatorcontrib><creatorcontrib>Gal, Gilad</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><title>Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects</title><title>Schizophrenia bulletin</title><addtitle>Schizophr Bull</addtitle><description>Impaired premorbid functioning prior to the onset of acute psychosis has frequently been noted in schizophrenia. This study examined retrospectively the premorbid status of patients in their first episode of psychosis in order to determine relationships with baseline symptoms, treatment response, and medication side effects. One hundred eleven schizophrenic and schizoaffective patients participating in a large prospective study of first episode schizophrenia were evaluated with the Premorbid Adjustment Scale (PAS). Premorbid functioning in males became progressively worse over time. Deficit state patients exhibited worse premorbid functioning. A third of patients exhibited sustained poor premorbid functioning. At various developmental stages, lower "sociability and withdrawal" scores correlated with increased time to treatment response, more severe negative symptoms, increased drug-induced parkinsonism, and deterioration of premorbid functioning. Various mean PAS scores predicted susceptibility to tardive dyskinesia. Our findings suggest that prior to acute psychosis onset there are certain behavioral precursors reflected in premorbid functioning that may predict subsequent illness manifestations. Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms.</description><subject>Adjustment Disorders - epidemiology</subject><subject>Adjustment Disorders - etiology</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Basal Ganglia Diseases - chemically induced</subject><subject>Basal Ganglia Diseases - epidemiology</subject><subject>Biological and medical sciences</subject><subject>Brief Psychotic Disorder</subject><subject>Cognition Disorders - diagnosis</subject><subject>Cognition Disorders - etiology</subject><subject>Drug Therapy</subject><subject>Female</subject><subject>Human</subject><subject>Humans</subject><subject>Inpatient</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Premorbidity</subject><subject>Psychiatric Symptoms</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychotic Disorders - complications</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Retrospective Studies</subject><subject>Schizoaffective Disorder</subject><subject>Schizophrenia</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - epidemiology</subject><subject>Sex Factors</subject><subject>Side Effects (Drug)</subject><subject>Social Alienation</subject><issn>0586-7614</issn><issn>1745-1701</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1DAUhSMEokPhFZCFVDY0g_8Sx5VY0KoFpCIQU9aW49wwrhI72E7F9OnxKIP4WbDywt-x7z1fUZwQvCZYstf-R-9Dd-vn4PQQ19Fs23lYa4wFFuJBsSKCVyURmDwsVrhq6lLUhB8VT2K8xZhwWdPHxRGpqJCYV6vi7nOA0YfWduhqdiZZ76z7hqxDG7O1937aBnBWn6EvMOj9LUoenesIg3WANrtxSn6Mp-gmgE4juJTBOHkX4RRp16GP0FmzBDe2A3TZ92BSfFo86vP48OxwHhdfry5vLt6X15_efbh4e13qPGEqm0YQ0lPRm4bXFDhtOtK2ICvWMADT8QbXFSMgGMMCKsFaqXkPIGvMteSYHRcvl3en4L_PEJMabTQwDNqBn6OimHJBmiaDL_4Bf1Wscn9MEl6x_0GUsopXnNMMvVkgE3yMAXo1BTvqsFMEq71C9bdCtShUB4U5__zwydyO0P1OH5xl4OQA6Gj00AftjI1_cJJKUu93f7VwetJqijujQ7JmgGjmkKUmFe9bxbCiiuYSfwIRxbvv</recordid><startdate>20040101</startdate><enddate>20040101</enddate><creator>Strous, Rael D.</creator><creator>Alvir, Jose Ma. J.</creator><creator>Robinson, Delbert</creator><creator>Gal, Gilad</creator><creator>Sheitman, Brian</creator><creator>Chakos, Miranda</creator><creator>Lieberman, Jeffrey A.</creator><general>National Institute of Mental Health</general><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7RZ</scope><scope>PSYQQ</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20040101</creationdate><title>Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects</title><author>Strous, Rael D. ; Alvir, Jose Ma. J. ; Robinson, Delbert ; Gal, Gilad ; Sheitman, Brian ; Chakos, Miranda ; Lieberman, Jeffrey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a527t-88711f27fc8462e428d1bbe95383eecd4806531e73307e573b9a4fee9604a9403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adjustment Disorders - epidemiology</topic><topic>Adjustment Disorders - etiology</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Basal Ganglia Diseases - chemically induced</topic><topic>Basal Ganglia Diseases - epidemiology</topic><topic>Biological and medical sciences</topic><topic>Brief Psychotic Disorder</topic><topic>Cognition Disorders - diagnosis</topic><topic>Cognition Disorders - etiology</topic><topic>Drug Therapy</topic><topic>Female</topic><topic>Human</topic><topic>Humans</topic><topic>Inpatient</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Premorbidity</topic><topic>Psychiatric Symptoms</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychotic Disorders - complications</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Retrospective Studies</topic><topic>Schizoaffective Disorder</topic><topic>Schizophrenia</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - epidemiology</topic><topic>Sex Factors</topic><topic>Side Effects (Drug)</topic><topic>Social Alienation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Strous, Rael D.</creatorcontrib><creatorcontrib>Alvir, Jose Ma. J.</creatorcontrib><creatorcontrib>Robinson, Delbert</creatorcontrib><creatorcontrib>Gal, Gilad</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via APA PsycArticles® (ProQuest)</collection><collection>ProQuest One Psychology</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Schizophrenia bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Strous, Rael D.</au><au>Alvir, Jose Ma. J.</au><au>Robinson, Delbert</au><au>Gal, Gilad</au><au>Sheitman, Brian</au><au>Chakos, Miranda</au><au>Lieberman, Jeffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects</atitle><jtitle>Schizophrenia bulletin</jtitle><addtitle>Schizophr Bull</addtitle><date>2004-01-01</date><risdate>2004</risdate><volume>30</volume><issue>2</issue><spage>265</spage><epage>278</epage><pages>265-278</pages><issn>0586-7614</issn><eissn>1745-1701</eissn><coden>SCZBB3</coden><abstract>Impaired premorbid functioning prior to the onset of acute psychosis has frequently been noted in schizophrenia. This study examined retrospectively the premorbid status of patients in their first episode of psychosis in order to determine relationships with baseline symptoms, treatment response, and medication side effects. One hundred eleven schizophrenic and schizoaffective patients participating in a large prospective study of first episode schizophrenia were evaluated with the Premorbid Adjustment Scale (PAS). Premorbid functioning in males became progressively worse over time. Deficit state patients exhibited worse premorbid functioning. A third of patients exhibited sustained poor premorbid functioning. At various developmental stages, lower "sociability and withdrawal" scores correlated with increased time to treatment response, more severe negative symptoms, increased drug-induced parkinsonism, and deterioration of premorbid functioning. Various mean PAS scores predicted susceptibility to tardive dyskinesia. Our findings suggest that prior to acute psychosis onset there are certain behavioral precursors reflected in premorbid functioning that may predict subsequent illness manifestations. Measures of premorbid functioning indicate that disease pathogenesis is manifest, albeit more subtly, prior to presentation of first psychotic symptoms.</abstract><cop>Oxford</cop><pub>National Institute of Mental Health</pub><pmid>15279045</pmid><doi>10.1093/oxfordjournals.schbul.a007077</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0586-7614 |
ispartof | Schizophrenia bulletin, 2004-01, Vol.30 (2), p.265-278 |
issn | 0586-7614 1745-1701 |
language | eng |
recordid | cdi_proquest_miscellaneous_20247188 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; APA PsycARTICLES; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
subjects | Adjustment Disorders - epidemiology Adjustment Disorders - etiology Adolescent Adult Adult and adolescent clinical studies Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Basal Ganglia Diseases - chemically induced Basal Ganglia Diseases - epidemiology Biological and medical sciences Brief Psychotic Disorder Cognition Disorders - diagnosis Cognition Disorders - etiology Drug Therapy Female Human Humans Inpatient Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Premorbidity Psychiatric Symptoms Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Psychotic Disorders - complications Psychotic Disorders - drug therapy Retrospective Studies Schizoaffective Disorder Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Schizophrenia - epidemiology Sex Factors Side Effects (Drug) Social Alienation |
title | Premorbid Functioning in Schizophrenia: Relation to Baseline Symptoms, Treatment Response, and Medication Side Effects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A50%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Premorbid%20Functioning%20in%20Schizophrenia:%20Relation%20to%20Baseline%20Symptoms,%20Treatment%20Response,%20and%20Medication%20Side%20Effects&rft.jtitle=Schizophrenia%20bulletin&rft.au=Strous,%20Rael%20D.&rft.date=2004-01-01&rft.volume=30&rft.issue=2&rft.spage=265&rft.epage=278&rft.pages=265-278&rft.issn=0586-7614&rft.eissn=1745-1701&rft.coden=SCZBB3&rft_id=info:doi/10.1093/oxfordjournals.schbul.a007077&rft_dat=%3Cproquest_cross%3E614391453%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=614391453&rft_id=info:pmid/15279045&rfr_iscdi=true |